124 related articles for article (PubMed ID: 15291347)
21. Stable mixed chimerism after T cell-depleted allogeneic hematopoietic stem cell transplantation using conditioning with low-dose total body irradiation and fludarabine.
Görner M; Kordelas L; Thalheimer M; Luft T; Pfeiffer S; Ustaoglu F; Punzel M; Weber-Nordt R; Moos M; Goldschmidt H; Ho AD
Bone Marrow Transplant; 2002 Apr; 29(7):621-4. PubMed ID: 11979314
[TBL] [Abstract][Full Text] [Related]
22. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
[TBL] [Abstract][Full Text] [Related]
23. Anti-T-lymphocyte globulin based non-myeloablative stem cell transplantation followed by HLA-identical donor lymphocyte infusion for hematologic malignancies.
Mao P; Wang S; Wang H; Li Q; Xu Y; Mo W; Ying Y; Zhu Z
Chin Med J (Engl); 2003 Jan; 116(1):70-3. PubMed ID: 12667392
[TBL] [Abstract][Full Text] [Related]
24. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
Carella AM; Lerma E; Dejana A; Corsetti MT; Celesti L; Bruni R; Benvenuto F; Figari O; Parodi C; Carlier P; Florio G; Lercari G; Valbonesi M; Casarino L; De Stefano F; Geniram A; Venturino M; Tedeschi L; Palmieri G; Piaggio G; Podestà M; Frassoni F; Van Lint MT; Marmont AM; Bacigalupo A
Haematologica; 1998 Oct; 83(10):904-9. PubMed ID: 9830799
[TBL] [Abstract][Full Text] [Related]
25. A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation.
Nikiforow S; Kim HT; Daley H; Reynolds C; Jones KT; Armand P; Ho VT; Alyea EP; Cutler CS; Ritz J; Antin JH; Soiffer RJ; Koreth J
Haematologica; 2016 Oct; 101(10):1251-1259. PubMed ID: 27354021
[TBL] [Abstract][Full Text] [Related]
26. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
27. Analysis of donor-type chimerism in lineage-specific cell populations after allogeneic myeloablative and non-myeloablative stem cell transplantation.
Miura Y; Tanaka J; Toubai T; Tsutsumi Y; Kato N; Hirate D; Kaji M; Sugita J; Shigematsu A; Iwao N; Ota S; Masauzi N; Fukuhara T; Kasai M; Asaka M; Imamura M
Bone Marrow Transplant; 2006 May; 37(9):837-43. PubMed ID: 16547484
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors.
Finke J; Brugger W; Bertz H; Behringer D; Kunzmann R; Weber-Nordt RM; Kanz L; Mertelsmann R
Bone Marrow Transplant; 1996 Dec; 18(6):1081-6. PubMed ID: 8971376
[TBL] [Abstract][Full Text] [Related]
29. Ex vivo T-cell-depleted allogeneic stem cell transplantation for hematologic malignancies: The search for an optimum transplant T-cell dose and T-cell add-back strategy.
Anandi P; Tian X; Ito S; Muranski P; Chokshi PD; Watters N; Chawla U; Hensel N; Stroncek DF; Battiwalla M; Barrett AJ
Cytotherapy; 2017 Jun; 19(6):735-743. PubMed ID: 28395942
[TBL] [Abstract][Full Text] [Related]
30. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.
Slavin S; Morecki S; Weiss L; Or R
J Hematother Stem Cell Res; 2002 Apr; 11(2):265-76. PubMed ID: 11983098
[TBL] [Abstract][Full Text] [Related]
31. Peritransplant use of ultraviolet-B irradiation (UV-B) therapy is detrimental to allogeneic stem cell transplantation outcome.
Yüksel M; Baron E; Camouse M; Cooper BW; Lazarus HM; Gerson SL; Laughlin MJ; Cooper KD; Gilliam A; Fu P; Stevens S; Koç ON
Biol Blood Marrow Transplant; 2006 Jun; 12(6):665-71. PubMed ID: 16737940
[TBL] [Abstract][Full Text] [Related]
32. Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
Lush RJ; Haynes AP; Byrne J; Cull GM; Carter GI; Pagliuca A; Parker JE; Mufti G; Mahendra P; Craddock CF; Lui Yin JA; Garg M; Prentice HG; Potter MN; Russell NH
Cytotherapy; 2001; 3(3):203-10. PubMed ID: 12171727
[TBL] [Abstract][Full Text] [Related]
33. Non-myeloablative allogeneic peripheral stem cell transplantation for multiple myeloma.
Ma SY; Lie AK; Au WY; Chim CS; Kwong YL; Liang R
Hong Kong Med J; 2004 Apr; 10(2):77-83. PubMed ID: 15075426
[TBL] [Abstract][Full Text] [Related]
34. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study.
Lewalle P; Triffet A; Delforge A; Crombez P; Selleslag D; De Muynck H; Bron D; Martiat P
Bone Marrow Transplant; 2003 Jan; 31(1):39-44. PubMed ID: 12621505
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R
Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931
[TBL] [Abstract][Full Text] [Related]
36. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
37. T Cell-Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an HLA-Matched Related or Matched Unrelated Donor Transplantation.
Gorgeis J; Zhang X; Connor K; Brown S; Solomon SR; Morris LE; Holland HK; Bashey A; Solh M
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1861-1866. PubMed ID: 27375124
[TBL] [Abstract][Full Text] [Related]
38. Reduced-intensity conditioning followed by unrelated umbilical cord blood transplantation for advanced hematologic malignancies: rapid engraftment in bone marrow.
Misawa M; Kai S; Okada M; Nakajima T; Nomura K; Wakae T; Toda A; Itoi H; Takatsuka H; Itsukuma T; Nishioka K; Fujimori Y; Ogawa H; Hara H
Int J Hematol; 2006 Jan; 83(1):74-9. PubMed ID: 16443557
[TBL] [Abstract][Full Text] [Related]
39. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies.
Branson K; Chopra R; Kottaridis PD; McQuaker G; Parker A; Schey S; Chakraverty RK; Craddock C; Milligan DW; Pettengell R; Marsh JC; Linch DC; Goldstone AH; Williams CD; Mackinnon S
J Clin Oncol; 2002 Oct; 20(19):4022-31. PubMed ID: 12351600
[TBL] [Abstract][Full Text] [Related]
40. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.
Bloor AJ; Thomson K; Chowdhry N; Verfuerth S; Ings SJ; Chakraverty R; Linch DC; Goldstone AH; Peggs KS; Mackinnon S
Biol Blood Marrow Transplant; 2008 Jan; 14(1):50-8. PubMed ID: 18158961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]